TFO Wealth Partners LLC Boosts Stock Position in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

TFO Wealth Partners LLC raised its stake in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC – Free Report) by 520.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,297 shares of the company’s stock after acquiring an additional 2,766 shares during the period. TFO Wealth Partners LLC’s holdings in GE HealthCare Technologies were worth $255,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of GEHC. Vanguard Group Inc. raised its stake in shares of GE HealthCare Technologies by 14.7% during the 3rd quarter. Vanguard Group Inc. now owns 44,531,402 shares of the company’s stock worth $3,029,917,000 after buying an additional 5,693,244 shares in the last quarter. Norges Bank purchased a new position in shares of GE HealthCare Technologies during the 4th quarter worth approximately $229,052,000. Ameriprise Financial Inc. raised its stake in shares of GE HealthCare Technologies by 84.4% during the 3rd quarter. Ameriprise Financial Inc. now owns 2,668,695 shares of the company’s stock worth $181,578,000 after buying an additional 1,221,436 shares in the last quarter. Envestnet Asset Management Inc. raised its stake in shares of GE HealthCare Technologies by 1,323.5% during the 3rd quarter. Envestnet Asset Management Inc. now owns 1,024,128 shares of the company’s stock worth $69,682,000 after buying an additional 952,182 shares in the last quarter. Finally, Invesco Ltd. raised its stake in shares of GE HealthCare Technologies by 21.4% during the 3rd quarter. Invesco Ltd. now owns 5,048,262 shares of the company’s stock worth $343,484,000 after buying an additional 889,297 shares in the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

Table of Contents

GE HealthCare Technologies Price Performance

Shares of NASDAQ:GEHC opened at $78.00 on Monday. The business’s fifty day moving average price is $83.92 and its two-hundred day moving average price is $80.91. The stock has a market cap of $35.60 billion, a PE ratio of 22.81, a price-to-earnings-growth ratio of 2.81 and a beta of 1.22. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.83 and a current ratio of 1.06. GE HealthCare Technologies Inc. has a one year low of $62.35 and a one year high of $94.50.

GE HealthCare Technologies (NASDAQ:GEHC – Get Free Report) last announced its earnings results on Tuesday, April 30th. The company reported $0.90 EPS for the quarter, meeting analysts’ consensus estimates of $0.90. The firm had revenue of $4.65 billion for the quarter, compared to analysts’ expectations of $4.80 billion. GE HealthCare Technologies had a return on equity of 25.32% and a net margin of 8.05%. GE HealthCare Technologies’s quarterly revenue was down 1.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.85 EPS. On average, analysts forecast that GE HealthCare Technologies Inc. will post 4.27 EPS for the current fiscal year.

GE HealthCare Technologies Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, May 15th. Stockholders of record on Friday, April 19th were issued a dividend of $0.03 per share. This represents a $0.12 annualized dividend and a dividend yield of 0.15%. The ex-dividend date of this dividend was Thursday, April 18th. GE HealthCare Technologies’s dividend payout ratio (DPR) is 3.51%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on GEHC shares. Mizuho cut their target price on GE HealthCare Technologies from $110.00 to $105.00 and set a “buy” rating for the company in a research note on Wednesday, May 1st. Morgan Stanley upped their price target on GE HealthCare Technologies from $74.00 to $86.00 and gave the stock an “equal weight” rating in a report on Monday, February 12th. Bank of America lowered their price target on GE HealthCare Technologies from $94.00 to $86.00 and set a “neutral” rating on the stock in a report on Wednesday, May 1st. UBS Group upgraded GE HealthCare Technologies from a “sell” rating to a “neutral” rating and upped their price target for the stock from $66.00 to $88.00 in a report on Monday, February 12th. Finally, Evercore ISI upped their price target on GE HealthCare Technologies from $93.00 to $100.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Five equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $94.09.

View Our Latest Analysis on GE HealthCare Technologies

Insider Transactions at GE HealthCare Technologies

In other news, CEO Jan Makela sold 66,955 shares of the firm’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $81.54, for a total transaction of $5,459,510.70. Following the sale, the chief executive officer now owns 63,348 shares in the company, valued at $5,165,395.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Jan Makela sold 66,955 shares of the firm’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $81.54, for a total transaction of $5,459,510.70. Following the sale, the chief executive officer now owns 63,348 shares in the company, valued at $5,165,395.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Frank R. Jimenez acquired 1,315 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The shares were acquired at an average price of $76.52 per share, for a total transaction of $100,623.80. Following the acquisition, the insider now directly owns 75,796 shares of the company’s stock, valued at $5,799,909.92. The disclosure for this purchase can be found here. Insiders have sold 90,482 shares of company stock worth $7,369,137 over the last quarter. 0.27% of the stock is currently owned by insiders.

About GE HealthCare Technologies

(Free Report)

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.